<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891913</url>
  </required_header>
  <id_info>
    <org_study_id>SY007002</org_study_id>
    <nct_id>NCT04891913</nct_id>
  </id_info>
  <brief_title>SY007 in Patients With Acute Ischemic Stroke</brief_title>
  <official_title>Phase Ib Clinical Study to Evaluate Safety, Tolerance，Pharmacokinetics and Efficacy of SY-007 After Intravenous Injection in Acute Ischemic Stroke Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1b multiple center, randomized, double-blind, placebo-controlled study is a dose&#xD;
      escalation trial evaluating the safety, tolerability, PK characteristics and efficacy of&#xD;
      SY-007 after injection in acute ischemicstroke patients. The immunogenicity of SY-007 will be&#xD;
      evaluated and this study will provide the recommended dosage for subsequent clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerance of SY-007</measure>
    <time_frame>From Day 0 to Day 90</time_frame>
    <description>Number of patients with treatment-emergent adverse events and number of patients who died over 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SY-007</measure>
    <time_frame>From Day 0 to Day 7</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SY-007</measure>
    <time_frame>From Day 0 to Day 7</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SY-007</measure>
    <time_frame>From Day 0 to Day 7</time_frame>
    <description>Time to Cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SY-007</measure>
    <time_frame>From Day 0 to Day 7</time_frame>
    <description>Terminal half life (T½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SY-007</measure>
    <time_frame>From Day 0 to Day 7</time_frame>
    <description>Clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SY-007</measure>
    <time_frame>From Day 0 to Day 7</time_frame>
    <description>Volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Excellent Outcome in Modified Rankin Scale（mRS) Score at Day 8, Day30, Day60, Day90</measure>
    <time_frame>Day 8, Day30, Day60, Day90</time_frame>
    <description>Excellent mRS is defined as mRS score of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale Score at Day 8, Day30, Day60, Day90</measure>
    <time_frame>Day 8, Day30, Day60, Day90</time_frame>
    <description>Modified Rankin Scale Score range from 0 to 5，higher score mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With National Institute of Health Stroke Scale (NIHSS) range from 0 to 1 at Day 8, Day30</measure>
    <time_frame>Day 8, Day30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in NIHSS Score at Day 8, Day30 range from 0 to 1 at Day 8, Day30</measure>
    <time_frame>Day 8, Day30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Excellent Outcome in Barthel index (BI) Score at Day 8, Day30, Day60, Day 90</measure>
    <time_frame>Day 8, Day30, Day60, Day 90</time_frame>
    <description>Excellent BI outcome is defined as a score of &gt;=95. BI consists of 10 items that measure a participant's daily functioning, specifically the activities of daily living and mobility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Cerebral infarction volume before and after treatment</measure>
    <time_frame>Baseline, Day 8, Day30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of SY-007</measure>
    <time_frame>From Day 0 to Day 30</time_frame>
    <description>Anti-Drug antibody evaluation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>15mg SY-007/ Placebo Repeat Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 15mg SY-007 or placebo twice a day for seven consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30mg SY-007/ Placebo Repeat Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 30mg SY-007 or placebo twice a day for seven consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg SY-007/ Placebo Repeat Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 60mg SY-007 or placebo twice a day for seven consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-007/ Placebo 15mg</intervention_name>
    <description>15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.</description>
    <arm_group_label>15mg SY-007/ Placebo Repeat Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-007/ Placebo 30mg</intervention_name>
    <description>30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.</description>
    <arm_group_label>30mg SY-007/ Placebo Repeat Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-007/ Placebo 60mg</intervention_name>
    <description>60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.</description>
    <arm_group_label>60mg SY-007/ Placebo Repeat Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Aged from18 Years to 80 Years&#xD;
&#xD;
          -  Within 24h after the onset of stroke symptoms (time the patient was last seen well)&#xD;
&#xD;
          -  Score range from 4 to 20 points, inclusive, on the NIHSS at randomization&#xD;
&#xD;
          -  Prior to index stroke, patient was able to perform basic activities of daily living&#xD;
             without assistance, mRS score≤1&#xD;
&#xD;
          -  Absence of intracranial hemorrhage on brain CT or MRI&#xD;
&#xD;
          -  Patients or legal representatives can give informed consent&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Venous thrombolytic therapy or endovascular treatments have been applied for patients;&#xD;
             or Patients plan to conduct these kind of treatments.&#xD;
&#xD;
          -  Glasgow score of Patients ≤8&#xD;
&#xD;
          -  Patients are receiving oral anticoagulants or INR&gt;3.0&#xD;
&#xD;
          -  Baseline blood platelet counts &lt;80*109/L&#xD;
&#xD;
          -  NIHSS score could not been obtained at baseline&#xD;
&#xD;
          -  FPG levels &lt; 50mg/dL or &gt;400mg/dL&#xD;
&#xD;
          -  Patients with Kidney disorder eGFR &lt;30 mL/min or patients need dialysis&#xD;
&#xD;
          -  Patients with Acute and Chronic hepatitis, or Liver diseases (AST or/and ALT &gt;2 ×&#xD;
             ULN(upper limit normal))&#xD;
&#xD;
          -  systolic blood pressure≥220mmHg or/and diastolic blood pressure≥120mmHg ; or Blood&#xD;
             pressure under 90/60mmHg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yun Xu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

